This article is more than 5 years old. Information may no longer be current.

Vosaroxin combination demonstrated improved survival in AML

SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of Texas MD Anderson Cancer Center, discusses data from the VALOR trial.

In the phase 3 study, combination therapy with vosaroxin (Quinprezo, Sunesis) and cytarabine was associated with longer OS in a cohort of more than 700 patients with acute myeloid leukemia.

“This is a combination… of vosaroxin and cytarabine that is associated with a significantly higher response rate in patients with relapse and refractory AML, is associated with improvement in median and overall survival and is not associated with increased early mortality,” Ravandi said. “This has been demonstrated in a well-designed, large, randomized trial and in my opinion, this regimen should be considered as a new standard for relapsed AML patients who are older than 60.”